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Abstract
Objective. To assess non-inferiority of s.c. to i.v. CT-P13 in RA.
Methods. Patients with active RA and inadequate response to MTX participated in this phase I/III double-blind study at
76 sites. Patients received CT-P13 i.v. 3 mg/kg [week (W) 0 and W2] before randomization (1:1) at W6 to CT-P13 s.c. via
pre-filled syringe (PFS) 120 mg biweekly until W28, or CT-P13 i.v. 3 mg/kg every 8 weeks until W22. Randomization was
stratified by country, W2 serum CRP and W6 body weight. From W30, all patients received CT-P13 s.c. In a usability sub-
study, patients received CT-P13 s.c. via auto-injector (W46–54) then PFS (W56–64). The primary endpoint was change
(decrease) from baseline in disease activity score in 28 joints (DAS28)-CRP at W22 (non-inferiority margin:0.6).
Results. Of 357 patients enrolled, 343 were randomized to CT-P13 s.c. (n¼ 167) or CT-P13 i.v. (n¼ 176) at W6. The
least-squares mean change (decrease) from baseline (standard error) in DAS28-CRP at W22 was 2.21 (0.22) for CT-P13
s.c. (n¼162) and 1.94 (0.21) for CT-P13 i.v. [n¼ 168; difference 0.27 (95% CI: 0.02, 0.52)], establishing non-inferiority.
Efficacy findings were similar between arms at W54. Safety was similar between arms throughout: 92 (54.8%; CT-P13
s.c.) and 117 (66.9%; CT-P13 i.v.) patients experienced treatment-emergent adverse events (from W6). There were no
treatment-related deaths or new safety findings. Usability was similar for CT-P13 s.c. via auto-injector or PFS.
Conclusion. CT-P13 s.c. was non-inferior to CT-P13 i.v. in active RA. The convenience of s.c. administration
could benefit patients.
Trial registration. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03147248.
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Rheumatology key messages
. CT-P13 s.c. was non-inferior in terms of efficacy to CT-P13 i.v., without altering safety signals.
. CT-P13 s.c. safety and efficacy were also well maintained after switching from CT-P13 i.v.
. Usability was similar and high for CT-P13 s.c. self-administration via auto-injector or pre-filled syringe.
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CT-P13, an infliximab biosimilar, is a chimeric monoclo-
nal antibody against TNF, with the same pharmaceutical
form, strength, composition and i.v. administration route
as reference infliximab [1]. CT-P13 i.v. has demonstrated
comparable efficacy, pharmacokinetics (PK), immuno-
genicity and safety to reference infliximab in AS and RA
[2, 3], and is approved for the same indications [4–7]. As
for other biosimilars, CT-P13 availability contributes to
reduced treatment costs and improved patient access
to biologics [8, 9].
An s.c. formulation of CT-P13 could offer potential
benefits for RA patients (particularly those who self-
administer therapy) [10] in terms of convenience, medic-
al resource optimization and health-care system costs
[10–12]. Preliminary data with an s.c.-administered ex-
perimental infliximab formulation in patients with RA re-
fractory to MTX suggest regular s.c. dosing could also
provide more stable serum drug concentrations vs i.v.
dosing, where flares may be experienced before the
next dose [13, 14]. However, small sample size, hetero-
geneity of the patient population and lack of a placebo
control arm limit the conclusions that can be drawn
from that study [13].
This randomized phase I/III study evaluated the s.c.
and i.v. formulations of CT-P13, in combination with
MTX, in patients with active RA with inadequate re-
sponse to MTX. Part 1 of the study [15, 16] was con-
ducted to find the optimal CT-P13 s.c. dose and Part 2
to demonstrate the non-inferiority of CT-P13 s.c. to CT-
P13 i.v. in terms of efficacy at week (W) 22. During Part
1, 48 patients were randomized (1:1:1:1) to receive CT-
P13 i.v. [3 mg/kg every 8 weeks (q8w)] or CT-P13 s.c.
[90, 120 or 180 mg every 2 weeks (q2w)] after initial CT-
P13 i.v. dose-loading at W0 and W2; mean serum con-
centrations consistently exceeded the target therapeutic
concentration (1 mg/ml) in all s.c. cohorts [15, 16]. The
CT-P13 s.c. dosing regimen for Part 2 was selected
based on Part 1 data [15, 16], population PK and PK-
pharmacodynamic (PD) modelling, and simulation results
comparing CT-P13 s.c. and CT-P13 IV i.v. dose regi-
mens in RA patients. Part 2, reported here, evaluated
the efficacy, PK, PD and safety of CT-P13 s.c. and CT-
P13 i.v. in patients with active RA. In addition, the us-
ability of CT-P13 s.c. administration via pre-filled syringe




This was a multicentre, randomized, double-blind, paral-
lel-group, non-inferiority, phase I/III study
(NCT03147248) initiated at 76 centres in multiple coun-
tries (Supplementary Table S1, available at
Rheumatology online). The study was performed accord-
ing to the principles of the Declaration of Helsinki and
International Conference on Harmonisation Good
Clinical Practice guidelines. Institutional review boards
or ethics committees at each centre approved the study
protocol. All patients provided written informed consent.
Patient and public involvement in research
This research was initiated without prior patient involve-
ment. Patients did not contribute to the study design,
were not involved in the interpretation of results and
were not invited to contribute to the writing/editing of
this document.
Patients
Full inclusion and exclusion criteria are provided in the
Supplementary Material, section ‘Methods’, available at
Rheumatology online. Patients were aged 18–75 years
with active RA for 6 months prior to first study drug
administration (day 0). RA was diagnosed according to
2010 ACR/EULAR criteria [17], and considered active if
patients had 6 swollen joints (28-joint count), 6 ten-
der joints (28-joint count) and a serum CRP concentra-
tion of >0.6 mg/dl. Eligible patients had an inadequate
response to 3 months of MTX therapy and had
received a stable MTX dose [12.5–25 mg/week (10–
25 mg/week in Republic of Korea)] for 4 weeks prior to
day 0.
Procedures
The treatment period comprised an i.v. dose-loading
phase (CT-P13 i.v. 3 mg/kg, administered by a 2-h i.v.
infusion at W0 and W2) for all patients followed by a
maintenance phase from W6 to W54 (W64 for usability
assessment) (Supplementary Fig. S1, available at
Rheumatology online). At W6, patients who had received
two full doses and displayed no safety concerns (investi-
gator’s opinion) were randomized (1:1) to receive an s.c.
injection of CT-P13 s.c. 120 mg q2w (administered via
PFS in 1 ml) or a 2-h i.v. infusion of CT-P13 i.v. 3 mg/kg
q8w (maintenance phase). Randomization was stratified
by country, W2 serum CRP concentration (0.6 vs
>0.6 mg/dl) and W6 body weight (100 vs >100 kg).
CT-P13 i.v. was manufactured by Celltrion, Inc.
(Incheon, Republic of Korea). The PFS device/material
and AI material were manufactured by Vetter Pharma-
Fertigung GmbH & Co. (Ravensburg, Germany). The AI
device was manufactured by SHL Pharma LLC
(Deerfield Beach, FL, USA). CT-P13 s.c. (or placebo
s.c.) was injected by a health-care professional at each
study visit; patients could self-inject at other treatment
weeks after appropriate training. Double-dummy match-
ing placebos were administered to maintain blinding
until W30, after which patients on CT-P13 i.v. were
switched to CT-P13 s.c. 120 mg q2w via PFS until W54.
Patients in Bulgaria, Poland and Russian Federation
received CT-P13 s.c. q2w via AI (W46–54) followed by
CT-P13 s.c. q2w via PFS (W56–64) to assess usability.
All patients received MTX [12.5–25 mg/week (10–25 mg/
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week in Republic of Korea), oral or parenteral dose] and
folic acid (5 mg/week, oral dose) throughout.
Outcome measures
Full details of efficacy, PK, PD, usability, safety and im-
munogenicity assessments are provided in the
Supplementary Material, available at Rheumatology online.
The primary objective was to demonstrate the non-
inferiority of CT-P13 s.c. to CT-P13 i.v. in terms of clinic-
al response according to change (decrease) from base-
line in DAS28-CRP at W22. CRP was assessed at a
central laboratory. Secondary efficacy endpoints
included mean change from baseline in DAS28 individ-
ual component, DAS28-CRP, DAS28-ESR, ACR re-
sponse (individual component, ACR20, ACR50, ACR70
and hybrid ACR score), EULAR response rate, Clinical
Disease Activity Index (CDAI) and Simplified Disease
Activity Index (SDAI). Patient-reported outcomes
included the HAQ and 36-Item Short Form Health
Survey (SF-36). Steady-state PK sampling time points
(W22–30) are shown in Supplementary Table S2, avail-
able at Rheumatology online. Secondary PK endpoints
included model-predicted AUCs, AUCW22–30, Cmax, and
Ctrough. In addition, observed Ctrough was evaluated up
to W54. Secondary PD endpoints included RF, anti-
CCP, CRP and ESR. Usability endpoints included as-
sessment of self-injection using PRE- and POST-Self-
Injection Assessment Questionnaires (SIAQs),
Successful Self-injection and the Potential Hazards
Checklist. Safety outcomes included treatment-
emergent adverse events (TEAEs), serious AEs (SAEs),
AEs of special interest (see Supplementary Material,
available at Rheumatology online), complement (C3, C4),
total haemolytic complement, signs and symptoms of
tuberculosis, local site pain and immunogenicity.
Statistical analysis
A sample size of 174 patients (87 per arm) was needed
to achieve 80% statistical power for demonstrating non-
inferiority of the primary endpoint between arms, based
on a 97.5% one-sided CI for the difference in mean
change (decrease) from baseline of DAS28-CRP at W22,
assuming a non-inferiority margin of 0.6, one-sided
alpha level of 2.5% and S.D. of 1.4. Anticipating a 20%
dropout rate, the sample size was estimated to be 218
patients (109 per arm). The primary efficacy analysis
was conducted on the all-randomized population and ef-
ficacy population using analysis of covariance; treatment
was considered a fixed effect. Country, W2 serum CRP
concentration (0.6 vs >0.6 mg/dl) and W6 body weight
(100 vs >100 kg) were covariates. The primary efficacy
endpoint, non-inferiority of CT-P13 s.c. to CT-P13 i.v.,
was concluded if the lower limit of the two-sided 95%
CI for the difference in change (decrease) from baseline
in DAS28-CRP at W22 between arms was more than
0.6. Sensitivity analysis with missing data imputation
for primary efficacy endpoint and statistical analyses for
secondary efficacy, PK, PD, safety and usability
endpoints are described in the Supplementary Material,
available at Rheumatology online. The all-randomized
and intention-to-treat populations were analysed by
randomized treatment at W6. Other populations were
analysed by actual treatment received: patients were
included in the CT-P13 s.c. arm if they received at least
one CT-P13 s.c. dose before W30. Statistical analysis
was performed using SAS software v9.4 (SAS Institute,
Inc., Cary, NC, USA). Population PK model was
employed to estimate the individual patient PK parame-
ters by a non-linear mixed-effect PK model using
NONMEM Version 7.2. An independent data safety mon-
itoring board monitored the study.
Results
Patients
Patients were recruited to Part 2 of the study between
30 October and 18 December 2017 (last visit of last pa-
tient: 15 April 2019). Overall, 528 patients were
screened, 357 were treated in the dose-loading phase
and 343 were randomized to CT-P13 s.c. (n¼ 167) or
CT-P13 i.v. (n¼176) at W6 (Fig. 1). One site in the
Russian Federation displayed significant Good Clinical
Practice non-compliance; 5 patients from this site were
excluded from all analysis populations. At W30, 160
patients remaining in the CT-P13 i.v. arm switched to
CT-P13 s.c. treatment. In the CT-P13 s.c. and i.v. arms,
141 and 145 patients, respectively, completed the study.
Overall, patient demographics and disease character-
istics were similar between arms (Table 1).
Efficacy
The primary outcome, the least-squares mean (SE)
change (decrease) from baseline at W22 in DAS28-CRP
for the efficacy population, was 2.21 (0.22) in the CT-
P13 s.c. arm (n¼162) and 1.94 (0.21) in the CT-P13 i.v.
arm (n¼168; Fig. 2A). Results for the all-randomized
population supported those for the efficacy population
(Fig. 2B). The difference between arms was 0.27 (95%
CI: 0.02, 0.52; efficacy population; Fig. 2C). The lower
bound of the CI was above the pre-specified non-infer-
iority margin (0.6), indicating non-inferiority of CT-P13
s.c. to CT-P13 i.v. Sensitivity analysis provided similar
results to the primary analysis (Supplementary Fig. S2,
available at Rheumatology online). CT-P13 s.c. appeared
to have similar improvement in efficacy up to W22 and
slightly improved efficacy at W30 vs CT-P13 i.v. with re-
spect to hybrid ACR score, ACR and EULAR responses,
DAS28-CRP, DAS28-ESR, CDAI and SDAI (Fig. 3;
Supplementary Tables S3 and S4, available at
Rheumatology online). After switching from CT-P13 i.v.
to CT-P13 s.c. at W30, substantial improvements in effi-
cacy measures were seen in the CT-P13 i.v. arm, with
similar efficacy to the CT-P13 s.c. arm observed at W54
(Supplementary Tables S3 and S4, available at
Rheumatology online). Mean scores for HAQ estimate of
physical ability generally decreased up to W54, and
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mean change from baseline was similar between arms
(Supplementary Table S4, available at Rheumatology on-
line). There were no notable differences between arms
in mean change from baseline in SF-36 Physical and
Mental Component summary scores (Supplementary
Fig. S3, available at Rheumatology online).
Pharmacokinetics
Mean CT-P13 serum levels were well maintained in both
arms up to W54 (Supplementary Fig. S4; Supplementary
Table S5, available at Rheumatology online). During the
PK monitoring period (W22–30), mean serum
concentration of CT-P13 s.c. gradually increased and
then decreased before the next administration. For CT-
P13 i.v., mean serum concentration peaked at the end
of the infusion at W22, then rapidly decreased towards
the pre-infusion level until W30. Mean predicted
AUCW22–30 for CT-P13 s.c. (20 926.6 hmg/ml) was
greater than the predicted AUCs at W22 for CT-P13 i.v.
(14 156.9 hmg/ml; Table 2). Model-predicted mean
Ctrough from W22 to W28 was consistently greater for
CT-P13 s.c. than CT-P13 i.v., but the model-predicted
mean Cmax was lower for CT-P13 s.c. than CT-P13 i.v.
(Table 2). Observed Ctrough values (Supplementary Table
S6, available at Rheumatology online) were consistent
FIG. 1 Patient disposition
aFive patients were excluded from all analysis populations because of significant Good Clinical Practice non-compli-
ance of the study centre. bThree patients (1 in the CT-P13 s.c. arm and 2 in the i.v. arm) with at least one major
protocol deviation and 1 patient (in the CT-P13 s.c. arm) with no efficacy assessment after week 6 were excluded
from the efficacy population. cOne patient randomized to the CT-P13 i.v. arm received CT-P13 s.c. treatment instead
of placebo s.c. treatment at week 14, thus receiving both CT-P13 i.v. 3 mg/kg and CT-P13 s.c. 120 mg at week 14.
This patient was included in the CT-P13 s.c. arm for the PD and safety populations and excluded from the efficacy
and PK populations. dOne patient with a major protocol deviation (CT-P13 i.v. arm) and 2 patients without PK con-
centration data (1 in each of the CT-P13 s.c. and i.v. arms) were excluded from the PK population. eAll 168 patients
eligible for usability assessment (patients in Bulgaria, Poland and Russian Federation continuing the study at week
46) were included in the usability population. PD, pharmacodynamics; PK, pharmacokinetics.
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with predicted Ctrough results from W22 to W28. Mean
observed Ctrough gradually increased in the CT-P13 i.v.
arm after switching to CT-P13 s.c. at W30 and was simi-
lar between arms from W44 to W52. In the CT-P13 s.c.
arm, mean serum concentration exceeded the target
therapeutic concentration (1 mg/ml) throughout the treat-
ment period (Supplementary Fig. S4, available at
Rheumatology online). Observed Ctrough values
exceeded this target for a greater proportion of patients
in the CT-P13 s.c. arm vs the CT-P13 i.v. arm. At W28,
81.6% of patients in the CT-P13 s.c. arm achieved
observed Ctrough >1 mg/ml; of those, 91.1% achieved
ACR20 response at W30 (Supplementary Table S7,
available at Rheumatology online).
Pharmacodynamics
In general, mean concentrations of PD parameters
decreased from baseline to W54 in both arms
(Supplementary Table S8, available at Rheumatology on-
line). In the CT-P13 i.v. arm, change from baseline in
CRP and ESR remained relatively consistent until W30;
after patients switched to CT-P13 s.c., CRP and ESR
generally decreased (W38–54).
Usability
Usability of CT-P13 s.c. via AI and PFS was high and
similar to each other: mean scores exceeded 7 for almost
all PRE-/POST-SIAQ domains from W46 to W64. Among
the three domains that have both PRE- and POST-SIAQ
scores, SIAQ scores of self-confidence were increased
after injection for both AI and PFS (Supplementary Table
S9, available at Rheumatology online). Almost all patients
successfully self-administered CT-P13 s.c. via AI and
PFS, and completed all instructions from the AI and PFS
Self-Injection Assessment Checklist at W46, W54, W56





Age, years 50.9 (12.17) 51.9 (12.42)
Sex, n (%)
Female 130 (77.8) 139 (79.0)
Race, n (%)
Asian/Oriental 1 (0.6) 2 (1.1)
White/Caucasian 145 (86.8) 151 (85.8)
Other 21 (12.6) 23 (13.1)
Screening height, cm 164.73 (9.20) 164.33 (9.31)
Screening weight, kg 73.01 (15.13) 72.75 (14.40)
Screening BMI, kg/m2 26.79 (4.42) 26.82 (4.13)
Time since RA diagnosis, years 6.82 (7.15) 6.41 (6.39)
DAS28-CRPc 6.01 (0.75) 5.86 (0.81)
DAS28-ESRc 6.70 (0.79) 6.56 (0.78)
Tender joint count (DAS28 assessment)c 16.1 (5.33) 14.8 (5.55)
Swollen joint count (DAS28 assessment)c 12.4 (4.42) 11.0 (4.32)
HAQ estimate of physical abilityc 1.58 (0.53) 1.58 (0.60)
CDAIc 42.53 (10.09) 39.59 (10.08)
SDAIc 44.36 (10.65) 41.86 (11.12)
Patient’s assessment of pain (VAS)c 69.09 (17.43) 68.57 (17.85)
Patient’s global assessment of disease activity (VAS)c 70.36 (15.80) 69.16 (17.40)
Physician’s global assessment of disease activity (VAS)c 70.22 (13.95) 68.80 (15.26)
ESR, mm/hc 41.8 (19.26) 44.5 (23.61)
CRP, mg/dlc 1.84 (2.39) 2.24 (3.53)
MTX dose at first administration (mg/week)d 17.01 (3.99) 17.40 (3.98)
MTX dose at first administration of maintenance phase (mg/week)d 16.98 (3.98) 17.40 (3.98)
Stratification factors
Weight (W6), n (%)
>100 kg 7 (4.2) 10 (5.7)
100 kg 160 (95.8) 166 (94.3)
Serum CRP (W2), n (%)
>0.6 mg/dl 34 (20.4) 47 (26.7)
0.6 mg/dl 133 (79.6) 129 (73.3)
aAnalysed according to randomized treatment at W6. bExcept where indicated otherwise, values are mean (S.D.). cEfficacy
population; CT-P13 s.c. (n¼165) and CT-P13 i.v. (n¼174). dSafety population; CT-P13 s.c. (n¼168), CT-P13 i.v. (n¼175).
CDAI, Clinical Disease Activity Index; DAS28, disease activity score in 28 joints; SDAI, Simplified Disease Activity Index;
VAS, visual analogue scale; W, week.
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and W64 (Supplementary Table S10, available at
Rheumatology online). The proportion of patients with
hazard-free self-injection was consistently high.
Safety
Incidence of TEAEs was higher with CT-P13 i.v. [117
(66.9%)] than CT-P13 s.c. [92 (54.8%)] during the main-
tenance phase (Table 3). Most TEAEs were grade 1 or 2
in intensity (Table 3; Supplementary Table S11, available
at Rheumatology online) and there were no notable dif-
ferences in safety profiles between arms after switching
from CT-P13 i.v. to CT-P13 s.c. (Supplementary Table
S12, available at Rheumatology online). Incidence of
TEAEs classified as infection during the maintenance
phase was higher with CT-P13 i.v. [60 (34.3%) patients]
than CT-P13 s.c. [49 (29.2%)] patients; Table 3).
Localized injection site reactions (ISRs) were reported
by 30 (17.9%; CT-P13 s.c.) and 22 (12.6%; CT-P13 i.v.)
patients (Table 3); 7 (4.0%) patients in the CT-P13 i.v.
arm reported an infusion-related reaction; and systemic
injection reactions occurred in 2 (1.2%; CT-P13 s.c.)
and 3 (1.7%; CT-P13 i.v.) patients. The majority of these
events were grade 1 or 2. Four (2.4%) patients in the
CT-P13 s.c. arm experienced a TEAE classified as
delayed hypersensitivity during the maintenance phase.
One of these patients underwent additional testing
11 days after the reaction: complement (C3; C4) and the
majority of clinical laboratory tests were normal and
anti-drug antibodies (ADAs) tested negative. ADA results
prior to delayed hypersensitivity were also negative for
the other 3 patients. A lower proportion of patients in
the CT-P13 s.c. vs i.v. arm experienced TEAEs leading
to discontinuation of study drug during the maintenance
phase [6 (3.6%) vs 14 (8.0%)].
Overall, 6 (3.6%; CT-P13 s.c.) and 13 (7.4%; CT-P13
i.v.) patients experienced at least one treatment-emergent
SAE in the maintenance phase (Supplementary Table
S13, available at Rheumatology online). Five patients died
during the maintenance phase: one (0.6%) in the CT-P13
s.c. arm, as a complication of hereditary haemochroma-
tosis; four (2.3%) in the CT-P13 i.v. arm, as a result of
myocardial infarction (n¼ 2), sudden death (n¼1) and
cardiac arrest (n¼1). All deaths were considered
FIG. 2 ANCOVA analysis of change (decrease) from baseline of DAS28-CRP at W22a
(A) L.S.M. (S.E.) change from baseline in DAS28-CRP at W22 (efficacy populationb). (B) L.S.M. (S.E.) change from base-
line in DAS28-CRP at W22 (all-randomized populationc). (C) Estimate of treatment difference (95% CI) in L.S.M.
change from baseline in DAS28-CRP at W22 for efficacyb and all-randomizedc populations. aChange (decrease) from
baseline for this primary analysis was defined as decrease from baseline and calculated as (DAS28-CRP at baseline
 DAS28-CRP at W22). bAnalysed according to actual treatment received. cAnalysed according to randomized treat-
ment at W6. dCriteria for non-inferiority met. ANCOVA, analysis of covariance; DAS28, disease activity score in 28
joints; L.S.M., least-squares mean; W, week.
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unrelated to study drug. One patient (0.6%; CT-P13 s.c.)
reported a malignancy (ovarian) during the maintenance
phase (Table 3).
Local site pain was high following the first administra-
tion of CT-P13 s.c. injection (CT-P13 s.c. arm: W6; CT-
P13 i.v.: W30; Supplementary Table S14, available at
Rheumatology online). Local site pain generally
decreased with repeated use of either administration
method and was similar between arms, although a slight
increase was reported in both arms at W54.
Immunogenicity
Immunogenicity was similar between arms: 114 (67.9%;
CT-P13 s.c.) and 129 (73.7%; CT-P13 i.v.) patients had
at least one positive post-treatment ADA result. In both
arms, the proportion of ADA-positive patients increased
after the dose-loading phase (Supplementary Fig. S5,
available at Rheumatology online) and remained similar
between arms throughout the study.
Discussion
The primary endpoint of Part 2 of this phase I/III study
was met by demonstrating that the mean change (de-
crease) from baseline in DAS28-CRP at W22 for patients
treated with CT-P13 s.c. was non-inferior to CT-P13 i.v.
Interestingly, the 95% CI for the treatment difference not
only lay within the pre-specified non-inferiority margin,
FIG. 3 Response (efficacy populationa)
(A) Proportion of patients achieving clinical response according to ACR20, ACR50 and ACR70 criteria. (B) Proportion
of patients with good/moderate response according to EULAR (CRP) and EULAR (ESR). aFrom W30 to W54, all
patients received CT-P13 s.c. and are analysed according to treatment received prior to W30. bAt W6, patients were
randomized to treatment; efficacy results up to W6 represent the efficacy of CT-P13 i.v. loading dose, regardless of
randomized arm. ACR20, 20% improvement in ACR criteria; ACR50, 50% improvement in ACR criteria; ACR70, 70%
improvement in ACR criteria; W, week.
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but was also above zero (Fig. 2C), providing evidence of
superiority of CT-P13 s.c. over CT-P13 i.v. at the 5%
statistical significance level. Overall, secondary efficacy
endpoints suggested slightly improved efficacy of CT-
P13 s.c. vs i.v. at W30, with similar efficacy observed
between arms at W54 after switching from CT-P13 i.v.
to CT-P13 s.c. Findings were similar for PD endpoints.
CT-P13 s.c. was well tolerated throughout the study.
Except for localized ISR, there were no clinically mean-
ingful differences in the safety profile of CT-P13 s.c. and
CT-P13 i.v. Usability of CT-P13 s.c. via AI and PFS was
high and did not differ between administration methods.
We compared i.v. dosing, using a body weight-based
dose administered q8w, with an s.c. regimen, using a
fixed dose (120 mg) administered q2w. Overall, the
mean serum concentration of CT-P13 was well main-
tained with s.c. and i.v. dosing. As a result of sparse PK
sampling time points, a non-linear mixed-effect PK
model estimated certain PK parameters for individual
patients. The predicted mean Ctrough was higher and the
predicted mean Cmax was lower with CT-P13 s.c. vs CT-
P13 i.v., reflecting the more frequent administration of
lower doses with the s.c. regimen and delayed drug ab-
sorption via the s.c. route [18, 19], leading to more con-
stant exposure over time vs i.v. dosing. After switching
to CT-P13 s.c. at W30, the PK profile in the CT-P13 i.v.
arm became similar to the CT-P13 s.c. arm. Previous
studies of i.v.-administered infliximab in RA patients
have suggested an association between Ctrough serum
concentrations 1mg/ml and clinical response [20–23].
In the CT-P13 s.c. arm, observed mean Ctrough levels
remained higher than this target throughout the mainten-
ance phase, suggesting that the s.c. dosing regimen
was appropriate. In addition, observed Ctrough values
exceeded this target for a greater proportion of patients
in the CT-P13 s.c. vs i.v. arm. Dose-loading with CT-
P13 i.v. was conducted prior to randomization at W6 to
ensure that steady-state serum concentrations exceed-
ing this therapeutic target could be rapidly achieved.
While the proportion of ADA-positive patients
increased after the dose-loading phase, CT-P13 s.c.
and i.v. immunogenicity was similar throughout the
study. As expected, more localized ISRs were reported
with CT-P13 s.c., but were rarely serious or severe in in-
tensity. No new safety findings were observed with CT-
P13 s.c., consistent with other s.c.- or i.v.-administered
biologics [24–26].
Clinical responses in our study are consistent with
previous reports. In the PLANETRA study, 73.4% of RA
patients treated with CT-P13 i.v. achieved ACR20 re-
sponse at W30 [3]. This compared with 86.1% (CT-P13
s.c.) and 76.4% (CT-P13 i.v.) of patients in our study;







n Mean (CV%) n Mean (CV%)
AUCs, hmg/ml
22 162 5311.5 (45.6) 165 14,156.9 (46.3)
24 160 5187.9 (45.3) N/A N/A
26 161 5273.1 (47.3) N/A N/A
28 160 5157.2 (46.6) N/A N/A
AUCW22–30, hmg/ml
22 162 20,926.6 (45.4) N/A N/A
Cmax, mg/ml
22 162 17.74 (40.87) 165 71.60 (16.89)
24 160 17.62 (40.73) N/A N/A
26 161 17.63 (41.10) N/A N/A
28 160 17.54 (40.63) N/A N/A
Ctrough, mg/ml
22 162 12.19 (54.25) 165 1.49 (168.41)
24 160 12.30 (53.96) N/A N/A
26 161 12.18 (53.42) N/A N/A
28 160 12.17 (54.58) N/A N/A
aPK parameters (AUCs, Cmax and Ctrough) were estimated from population PK modelling, and AUCW22–30 for the CT-P13
s.c. arm was estimated due to the different dosing interval of s.c. and i.v. administration [every 2 weeks (W6–28) and every
8 weeks (W6, W14 and W22), respectively]. bAnalysed according to actual treatment received. AUCs, model-predicted area
under the concentration–time curve at steady-state between W22 and W30; AUCW22–30, model-predicted area under the
concentration–time curve due to different dosing interval of s.c. and i.v. administration using population PK model; Cmax,
model-predicted maximum serum concentration after study drug administration; Ctrough, model-predicted trough serum
concentration; CV%, per cent coefficient of variation; N/A, not applicable; PK, pharmacokinetic; W, week.
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W54 findings were also similar to PLANETRA results at
W54 [27]. Similarly, during a phase I study of an experi-
mental s.c. infliximab formulation, 80–87% of RA patients
achieved ACR20 response 2 weeks post-treatment [13],
consistent with our W22 results. Taken together, these
data suggest that s.c. administration of infliximab can
achieve good clinical response rates in RA patients.
We report a robust randomized study using well-
established outcome measures, conducted across 12
countries, which suggests findings should be applicable
to the wider RA patient population. Nevertheless, the
study had some limitations. Patients with a BMI  35
were excluded, and follow-up was limited (56–
66 weeks, depending on country). Future studies should
investigate longer-term efficacy and safety of CT-P13
s.c. and effects in patients with high body weight/BMI.
In conclusion, CT-P13 s.c. was non-inferior in efficacy
to CT-P13 i.v. in patients with active RA. Efficacy and
safety of CT-P13 treatment were well maintained follow-
ing switching from CT-P13 i.v. to s.c. CT-P13 s.c. could
represent a beneficial treatment option because of the
alternative, convenient administration method.
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Total TEAEs, n 309 313
Patients with 1 TEAE 92 (54.8) 117 (66.9)
Treatment-related TEAE 73 (43.5) 72 (41.1)
TEAE grade 3 13 (7.7) 8 (4.6)
Total TESAEs, n 8 15
Patients with 1 TESAE 6 (3.6) 13 (7.4)
Treatment-related TESAE 3 (1.8) 4 (2.3)
Patients with 1 TEAE leading to discontinuation of study drug 6 (3.6) 14 (8.0)
Patients with 1 TEAE classified as localized ISR 30 (17.9)e 22 (12.6)e
Patients with 1 TEAE classified IRRb 0 7 (4.0)f
Patients with 1 TEAE classified as SIRb 2 (1.2)g 3 (1.7)g
Patients with 1 TEAE classified as delayed hypersensitivityc 4 (2.4)h 0
Patients with 1 TEAE classified as infections 49 (29.2) 60 (34.3)
Most common infections and infestationsd
Viral upper respiratory tract infection 10 (6.0) 14 (8.0)
Upper respiratory tract infection 8 (4.8) 13 (7.4)
Latent tuberculosis 8 (4.8) 10 (5.7)
Urinary tract infection 9 (5.4) 7 (4.0)
Bronchitis 5 (3.0) 4 (2.3)
Patients with 1 TEAE classified as malignancy 1 (0.6) 0
Data are n (%) unless stated otherwise. aAll patients received CT-P13 s.c. from W30 to W54 (or W64 for patients partici-
pating in the usability assessment) and were analysed according to actual treatment received prior to W30. bIRRs occurred
between start of administration and 24 h after the i.v. infusion of CT-P13 or placebo. SIRs occurred between start of ad-
ministration and 24 h after the s.c. injection of CT-P13 or placebo. cTEAEs classified as delayed hypersensitivity were
defined as IRRs or SIRs that occurred after 24 h from study drug or placebo administration. dReported by 3% of patients
in either treatment arm. eAll localized ISRs were grade 1 or 2 and considered by the investigator to be related to study
drug, except for one treatment-related grade 3 localized ISR in each treatment arm, and one grade 2 localized ISR consid-
ered unrelated to study treatment in the CT-P13 s.c. arm. fOne grade 3 IRR; all other IRRs were grade 1 or 2. gAll SIRs
were grade 1 or 2. hThree grade 2 delayed hypersensitivity reactions and one grade 3 reaction. IRR, infusion-related reac-
tion; ISR, injection site reaction; SIR, systemic injection reaction; TEAE, treatment-emergent adverse event; TESAE, treat-
ment-emergent serious adverse event; W, week.
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over the 1-year treatment period and after switching from
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